

**CONTACT PERSON FOR MORE INFORMATION:** Thomas J. Trabucco, Director, Office of External Affairs (202) 942-1640.

Dated: February 23, 1999.

**John J. O'Meara,**

*Secretary to the Board, Federal Retirement Thrift Investment Board.*

[FR Doc. 99-4863 Filed 2-23-99; 3:14 pm]

BILLING CODE 6760-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention (CDC)

#### Board of Scientific Counselors, National Institute for Occupational Safety and Health: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Public Law 92-463) of October 6, 1972, that the Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH), of the Department of Health and Human Services, has been renewed for a 2-year period through February 3, 2001.

For information, contact Bryan Hardin, Ph.D., Deputy Director, NIOSH, CDC, 1600 Clifton Road, m/s D35, Atlanta, Georgia 30333. Telephone 404/639-3773, e-mail bdh1@cdc.gov.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: February 19, 1999.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 99-4648 Filed 2-24-99; 8:45 am]

BILLING CODE 4163-19-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Endocrinologic and Metabolic Drugs Advisory Committee; Amendment of Notice

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an

amendment to the notice of meeting of the Endocrinologic and Metabolic Drugs Advisory Committee Meeting that is scheduled for March 26, 1999. This meeting was announced in the **Federal Register** of February 8, 1999 (64 FR 6100). The amendment is being made to reflect a change in the agenda of the meeting notice. There are no other changes.

#### FOR FURTHER INFORMATION CONTACT:

Kathleen R. Reedy or LaNise Giles, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12536.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of February 8, 1999 (64 FR 6100), FDA announced that the meeting of the Endocrinologic and Metabolic Drugs Advisory Committee would discuss experience since approval for marketing, benefits, and risks of Rezulin™ (troglitazone, Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert) in the treatment of type 2 diabetes mellitus. This amendment is being made to provide new information regarding the agenda of the meeting. On page 6100, in the third column, the *Agenda* is amended to read as follows:

*Agenda:* The committee will discuss: (1) Experience since approval for marketing, benefits, and risks of Rezulin™ (troglitazone, Parke-Davis Pharmaceutical Research, a Division of Warner-Lambert) in the treatment of type 2 diabetes mellitus; and (2) new drug application 20-720; S12 Rezulin™ for triple therapy with sulfonylurea and metformin in the treatment of type 2 diabetes mellitus.

Dated: February 16, 1999.

**Michael A. Friedman,**

*Deputy Commissioner for Operations.*

[FR Doc. 99-4611 Filed 2-24-99; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:

*Name:* Safety and Occupational Health Study Section (SOHSS) [Task Group], National Institute for Occupational Safety and Health (NIOSH).

*Times and Dates:* 9:30 a.m.-11:30 a.m. March 12, 1999.

*Place:* Teleconference, NIOSH, 1095 Willowdale Road, Morgantown, WV, 26505.

*Status:* Open 9:30 a.m.-9:45 a.m. March 12, 1999. Closed 9:45 a.m.-11:30 a.m. March 12, 1999.

*Purpose:* The Safety and Occupational Health Study Section [Task Group] will review, discuss, and evaluate grant application(s) received in response to the Institute's standard grants review and funding cycles pertaining to research issues in occupational safety and health and allied areas.

It is the intent of NIOSH to support broad-based research endeavors in keeping with the Institute's program goals which will lead to improved understanding and appreciation for the magnitude of the aggregate health burden associated with occupational injuries and illnesses, as well as to support more focused research projects which will lead to improvements in the delivery of occupational safety and health services and the prevention of work-related injury and illness. It is anticipated that research funded will promote these program goals.

*Matters to be Discussed:* The meeting will convene in open session from 9:30-9:45 a.m. on March 12, 1999, to address matters related to the conduct of Study Section business. The remainder of the meeting will proceed in closed session. The purpose of the closed sessions is for the Safety and Occupational Health Study Section to consider safety and occupational health related grant applications. These portions of the meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6) title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92-463.

Agenda items are subject to change as priorities dictate.

*Contact Person For More Information:*

Pervis C. Major, Ph.D., Scientific Review Administrator, Office of Extramural Coordination and Special Projects, Office of the Director, NIOSH, 1095 Willowdale Road, Morgantown, West Virginia 26505. Telephone 304/285-5979.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: February 19, 1999.

**Carolyn J. Russell,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 99-4649 Filed 2-24-99; 8:45 am]

BILLING CODE 4163-19-P